Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Hematopathology Tumor Board: Case Studies and Diagnostic Challenges …

UChicago Medicine

G. Venkataraman, A. Perry, K. Cahill, A. Akmatbekov, L. Wu

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

Novel Therapeutics for T-Cell Lymphoma: Navigating Regulatory Pitfal…

UChicago Medicine

S. Iyer

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

Monia Marchetti

Treatment-Related Quality of Life in MF

Winship Cancer Institute - Emory University

A. Hunter

LGL Leukemia: History, Diagnosis, and Treatment Options

BMFcases

T. Bat

T-Cell Lymphomas: Impact of Classification on Treatment

19th Annual International Ultmann Chicago Lymphoma Symposium

N. Mehta-Shah

Diagnosis and Evidence-Based Management of T-Cell Lymphoma

i3 Health

A. Goodman

SOHO 2022: Biology and Treatment of LGL Leukemia

SOHO 2022 Tenth Annual Meeting

T. Loughran

Expert Case Discussions: LGL Leukemia

BMFcases

T. Loughran

What We Recommend for Aggressive B- and T-Cell Lymphomas in 2022

Indy Hematology Review

J. Leonard

SOHO 2022 Next Questions: T-Cell Lymphoma

SOHO 2022 Tenth Annual Meeting

S. Iyer

Standard Management of Aggressive Lymphomas and Data on Emerging The…

Indy Hematology Review

J. Leonard

MSKCC 2021 Update on Therapeutic Advances in T-Cell Lymphoma: Subtyp…

i3 Health

S. Horwitz

Review and Updates of New and Upcoming Cytopathology Reporting Syste…

Houston Methodist

E. M. Jacobi

SOHO 2022: Challenging Cases in Rare T-Cell Lymphomas

SOHO 2022 Tenth Annual Meeting

S. Barta